ThermoGenesis (NASDAQ:THMO) Upgraded to “Hold” by Zacks Investment Research

Share on StockTwits

ThermoGenesis (NASDAQ:THMO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Thursday, reports.

According to Zacks, “ThermoGenesis Holdings Inc. develops, commercializes and markets automated technologies for CAR-T and other cell-based therapies. The company markets solutions for automated clinical biobanking, point-of-care applications and automation for immuno-oncology. ThermoGenesis Holdings Inc., formerly known as Cesca Therapeutics Inc., is based in Rancho Cordova, California. “

Separately, HC Wainwright lowered their price target on ThermoGenesis from $9.50 to $8.50 and set a “buy” rating for the company in a report on Friday, November 13th.

Shares of THMO opened at $2.41 on Thursday. The stock has a 50 day moving average price of $2.26 and a 200 day moving average price of $3.36. The company has a quick ratio of 1.43, a current ratio of 2.22 and a debt-to-equity ratio of 0.93. The company has a market capitalization of $18.79 million, a price-to-earnings ratio of -0.49 and a beta of 3.26. ThermoGenesis has a 52-week low of $1.63 and a 52-week high of $14.18.

ThermoGenesis (NASDAQ:THMO) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.27). The business had revenue of $2.36 million during the quarter, compared to analyst estimates of $3.88 million. ThermoGenesis had a negative net margin of 154.77% and a negative return on equity of 427.02%. On average, equities analysts anticipate that ThermoGenesis will post -1.77 EPS for the current fiscal year.

A hedge fund recently bought a new stake in ThermoGenesis stock. Diametric Capital LP acquired a new stake in ThermoGenesis Holdings, Inc. (NASDAQ:THMO) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 38,257 shares of the company’s stock, valued at approximately $111,000. Diametric Capital LP owned about 0.57% of ThermoGenesis at the end of the most recent quarter. 4.24% of the stock is currently owned by institutional investors and hedge funds.

About ThermoGenesis

ThermoGenesis Holdings, Inc develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR)-T and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market.

Recommended Story: What is the formula for calculating total return?

Get a free copy of the Zacks research report on ThermoGenesis (THMO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ThermoGenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ThermoGenesis and related companies with's FREE daily email newsletter.